Xiamen Kingdomway Group's Worm Infection Drug Approved in China
I'm PortAI, I can summarize articles.
(MT Newswires) -- Chinese agricultural officials approved Xiamen Kingdomway Group's (SHE:002626) praziquantel antihelmintic drug, according to a Thursday filing by the fortified food and feed additive manufacturer with the Shenzhen bourse. The registration validity of the worm infection drug is five years, from Sept. 3, 2025, to Sept. 2, 2030.
Source: marketscreener The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments